Oxford BioMedica Announces US$1 million Milestone Payment from Pfizer
— Phase I clinical trial for 5T4-targeted antibody therapy underway — Oxford, UK – 28 August 2013: Oxford BioMedica (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Announced as Regenerative Medicine and Cell Therapy Funding Competition Winner by the UK’s innovation agency, the Technology Strategy Board
— Funding to be received for the development of a novel therapeutic treatment to engineer corneas to resist graft rejection — Oxford,… Read More
Oxford BioMedica Announces Publication of TroVax® Phase II Analyses in Peer-Reviewed Medical Journal
— Results from Phase II trial in prostate cancer published in Cancer Immunology, Immunotherapy — — Favourable tolerability and biomarker… Read More
Oxford BioMedica: Notice of Interim Results
Results date: 29 August 2013 Oxford, UK – 23 July 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, will be announcing its interim results for the six months ended 30 June… Read More
Oxford BioMedica Announces Update on Glaucoma-GT
— Pre-clinical collaboration with Mayo Clinic on track — Oxford, UK – 1 July 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB),… Read More
Oxford BioMedica plc Change of Adviser and Broker
Oxford, UK – 6 June 2013: Oxford BioMedica (“the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has appointed Nomura Code Securities Limited as its sponsor, financial adviser and broker with immediate effect. Read More
Oxford BioMedica plc Management and Board change
Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that Dr Stuart Naylor will step down from the Board of Oxford BioMedica and as Chief Scientific Officer… Read More
Oxford BioMedica: Clinical Trial Update
Oxford, UK – 3 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has voluntarily paused recruitment into the RetinoStat® Phase I, StarGen™ Phase I/IIa… Read More
Oxford BioMedica Interim Management Statement
Oxford, UK – 16 May 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 15 May 2013. Read More
Oxford BioMedica Announces Update from ARVO 2013
– UshStat® video selected to showcase theme of “Life-changing Research” — Oxford, UK – 9 May 2013: Oxford BioMedica plc… Read More
Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration
Oxford, UK – 1 May 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector… Read More
Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Mesothelioma
— First patient treated at Velindre Cancer Centre, Wales (UK) — Oxford, UK – 7 March 2013: Oxford BioMedica plc (“Oxford BioMedica” or… Read More